To address whether selective inhibition of BCL2 in combination with HER2 blockade would induce a similar response, we examined the consequences of lapatinib treatment in combination with the BCL2-specific inhibitor ABT-199.29 ABT-199 treatment did not induce thrombocytopenia, which was consistent with BCL2-specific inhibition29 (Supplementary Fig. 6). The gene discussed is BCL2; the disease is Thrombocytopenia.